CardioGenics Holdings Inc
OTC:CGNH
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| US |
|
CardioGenics Holdings Inc
OTC:CGNH
|
9.6k USD |
59%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.2B USD |
113%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
153.9B USD |
99%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
139.7B USD |
33%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
98.2B USD |
23%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
96.8B AUD |
16%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.4B USD |
15%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
60.1B USD |
-258%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
CardioGenics Holdings Inc
Glance View
CardioGenics Holdings, Inc. is a biotechnology company, which engages in the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2004-06-09. The firm has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on CardioGenics Holdings Inc's most recent financial statements, the company has ROE of 58.8%.
You don't have any saved screeners yet